Objective: Constitutive photomorphogenesis 9 subunit 6, as one subunit of the constitutive photomorphogenesis 9, plays an important role in tumor development. The aim of the study was to investigate the clinical and prognostic implications of constitutive photomorphogenesis 9 subunit 6 protein in breast cancer. Methods: We examined mastectomy specimens from 92 invasive breast cancers and matched with 20 adjacent non-cancerous tissues using immunohistochemistry. Results: The positive expressions of constitutive photomorphogenesis 9 subunit 6 protein in invasive breast cancer and adjacent non-cancerous tissue were 32.61% (30 of 92) and 10% (2 of 20), respectively. The positive expression of constitutive photomorphogenesis 9 subunit 6 protein was related to tumor size, histological type and lymph node metastasis (P ¼ 0.015, 0.009 and 0.009, respectively). After univariate analysis, constitutive photomorphogenesis 9 subunit 6-positive expression was only found to be significantly related to mutant-type P53 expression (P , 0.001). Spearman's correlation analysis was used to demonstrate negative correlations between constitutive photomorphogenesis 9 subunit 6 and mutant-type P53 (r ¼ 20.417). Constitutive photomorphogenesis 9 subunit 6 positive was associated with both poorer breast cancer-specific survival in 92 cases and in the lymph node-positive group (P ¼ 0.007 and 0.024, respectively). In the Cox regression test, constitutive photomorphogenesis 9 subunit 6 protein was not shown to be an independent prognostic factor for breast cancer. Conclusion: Constitutive photomorphogenesis 9 subunit 6 might be a new potential biomarker for breast cancer. However, the underlying mechanisms of constitutive photomorphogenesis 9 subunit 6's involvement are still unclear.
INTRODUCTION
Breast carcinoma is the most frequently diagnosed cancer and the leading cause of cancer death in females worldwide (1) . Although the incidence of breast cancer in Asia is increasing, the survival rate among Asian patients with breast cancer is approximately half that of patients in Western countries (2) .
Breast cancer is regarded as a heterogeneous disease, not only on the pathologic and clinical levels, but also on the molecular level (3) . In recent years, there has been an explosion of systemic therapies against breast cancer, bringing new hope and excitement, but is limited to the varied clinical course of breast cancer (4, 5) . Hormonal therapies (tamoxifen, anti-estrogens) and adjuvant chemotherapy [trastuzumab (Herceptin)] have benefited patients with estrogen receptor (ER)-positive cancers and human epidermal growth factor receptor 2 (HER2/neu) overexpressing cases (6, 7) . Therefore, there are prognostic ramifications that need to be investigated concerning the status of these known proteins in breast cancer.
Constitutive photomorphogenesis 9 subunit 6 (CSN6), as one subunit of the constitutive photomorphogenesis 9 (COP9), was originally identified from Arabidopsis mutants that mimic light-induced seedling development when grown in the dark (8) . It has recently received attention as a marker for being frequently observed in esophageal squamous cell carcinoma (9) , breast cancer (10), pancreatic carcinoma (11) and T-cell leukemia (12) .
Recently, Lee's laboratory demonstrated that CSN6 increased stability of MDM2 by inhibiting its self-ubiquitination. MDM2 is a RING domain containing E3 ubiquitin ligase, toward the tumor suppressor p53, thereby mediating wild-type P53 degradation by nuclear and cytoplasmic proteasomes. Thus, CSN6 plays an important role in regulating the MDM2-p53 pathway and tumor development (13) . However, the clinical and prognostic implications of CSN6 as a marker and correlation with mutant-type P53 for breast cancer are still unclear.
Currently, the studies addressing CSN6 expression in Asian breast cancer patients are rare. Therefore, we examined 92 mastectomy specimens obtained from patients with breast cancers to investigate the expression of CSN6 in relation to clinicopathological features and immunohistochemical markers in breast cancer, and to lay a foundation for the prognostic impact of CSN6 expression.
PATIENTS AND METHODS

PATIENTS AND TISSUE SPECIMENS
For the present study, we evaluated 92 patients who had histologically confirmed invasive breast cancer and underwent radical operations in the Surgical Oncology Department of the First Affiliated Hospital of the China Medical University between July 2001 and September 2003. The inclusion criteria were as follows: (i) curative operations were carried out; (ii) resected specimens were pathologically examined; (iii) more than 10 lymph nodes were pathologically examined after operation and (iv) a complete medical record was available. The study protocol was approved by the Ethics Committee of China Medical University.
EXPERIMENTAL MATERIALS
A polyclonal rabbit antihuman CSN6 antibody (dilution1:300) was obtained from BIOMOL International (USA). Monoclonal mouse antihuman ER antibody (dilution1:100), monoclonal mouse antihuman progesterone receptor (PR) antibody (dilution1:100), monoclonal mouse antihuman Ki-67 antibody (dilution1:100), monoclonal mouse anti-HER2/neu antibody (dilution 1:100) and polyclonal rat antihuman mutant-type tumor protein 53 (P53) antibody (dilution 1:100) was purchased from Zhongshan Goldenbridge Ltd (Shanghai, China).
IMMUNOHISTOCHEMISTRY EXPERIMENTAL PROCEDURES
We fixed thin slices of tumor tissue of all cases received in our histopathology unit in 4% formaldehyde solution (pH 7.0) for periods not exceeding 24 h. The tissues were processed routinely for paraffin embedding, and 4 mm-thick sections were cut and placed on glass slides coated with 3-aminopropyl triethoxysilane for immunohistochemistry. Tissue samples were stained with hematoxylin and eosin to determine histological type and grade of tumors.
All cases of breast tumor tissues were cut at a thickness of 4 mm using a microtome. The sections were mounted on microscope slides, air-dried and then fixed in a mixture of 50% acetone and 50% methanol. The sections were then de-waxed with xylene, gradually hydrated with gradient alcohol and washed with PBS. The sections were incubated overnight at 48C with the primary antibody after incubating with 3% H 2 O 2 for 10 min at room temperature. Following washings with PBS, sections were incubated for 20 min at 378C in the Polymer Helper (PV-9000; Zhongshan Goldenbridge Ltd.). Following washing, the secondary antibody ( poly peroxidase-anti-mouse/rabbit immunoglobulin; Zhongshan Goldenbridge Ltd.) was then applied to the sections for 30 min at 378C. The immunoreactive products were visualized by catalysis of 3,3-diaminobenzidine following extensive washings. Sections were then counterstained in Gill's Hematoxylin and dehydrated in ascending grades of methanol before clearing in xylene, and mounting under a coverslip.
CSN6 expression was classified semi-quantitatively according to the following criteria: 0 if ,1% of neoplastic cells discretely expressed CSN6 in their nucleus; 1þ if 1 and ,10% of morphologically unequivocal neoplastic cells discretely expressed CSN6 in their nucleus and, 2þ if 10% of morphologically unequivocal neoplastic cells discretely expressed CSN6 in their nucleus. Samples scored as 1þ or 2þ were considered positive.
Nuclear staining for ER, PR, Ki-67 and mutant-type P53 was graded 1þ if ,10% of the cells were stained, 2þ if 10 -50% of the cells were stained and 3þ if .50% of the cells were stained. We considered grades 2þ and 3þ as positive, whereas we considered the absence of staining and 1þ staining as negative. HER-2/neu was scored according to the standardized criteria established by Wolff et al. (14); here, only score 3þ (defined as uniform intense membrane staining of 30% of invasive tumor cells) was considered positive.
STATISTICAL ANALYSIS
All data were analyzed with SPSS statistics software (Version 16.0, Chicago, IL, USA). Relationships between tumor markers and other parameters were studied using a x 2 test, Fisher's extract test or independent t-test. Spearman's correlation analysis was used to study the correlation among ER, PR, Ki67, HER-2/neu, mutant-type P53, Ki-67 and CSN6 protein expression. The values of correlation coefficient (r) were regarded as between 21 and 1. The numbers between Jpn J Clin Oncol 2013;43 (12) 1171 are like a scale, where 21 indicates a very strong link, 0 no link and 1 also a very strong link. The difference between 1 and 21 is that 1 is a positive correlation and 21 is a negative correlation. Disease-specific survival was analyzed using the Kaplan -Meier method. The log-rank test was used to analyze survival differences. Multivariate analysis was carried out using the Cox proportional hazards model selected in forward stepwise. A P value of ,0.05 was considered statistically significant.
RESULTS
PATIENT CHARACTERISTIC
The mean age of the 92 patients studied was 48.41 years (range 32 -80 years). Within the total sample, 44 patients had no lymph node metastasis and 22 with pN1, 17 with pN2 and 9 with pN3 metastasis ( An immunohistochemical examination showed that CSN6 was located in the nucleus of breast cancers (Fig. 1A) . Strong, weak and negative expressions of CSN6 are shown in Figure 1A -C, respectively. The expressions of CSN6, HER2/ neu and mutant-type p53 in serial sections are presented in Figure 1A , D and E, respectively. The positive expression of CSN6 protein in adjacent non-cancer tissue was 10% (2 of 20). Moreover, we observed that positive expression of CSN6 protein was related to tumor size, histological grade and lymph node metastasis of breast cancer (P ¼ 0.015, 0.009 and 0.009, respectively). It was not associated, however, with age or molecular type (P ¼ 1.000 and 0.148, respectively; Table 1 ).
CSN6 EXPRESSION AND IMMUNOHISTOCHEMICAL MARKERS
After univariate analysis, the CSN6-positive expression rate was found to be significantly higher in HER2/neu þ and mutant-type P53 2 cases than in HER/neu 2 or mutant-type P53 þ cases (P ¼ 0.048 and P , 0.001, respectively) ( Table 2 ). However, no significant difference in CSN6 expression, however, was observed in ER, PR or Ki-67cases 
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(P ¼ 0.736, 0.992 and 0.649, respectively) ( Table 2) . We carried out logistic analysis on the above factors in order to exclude the effects of confounding factors. After multivariate analysis, HER2/neu was not found to be related to CSN6 expression (P ¼ 0.229) ( Table 3) .
CORRELATION AMONG ER, PR, MUTANT-TYPE P53, HER2/NEU, KI-67 AND CSN6 EXPRESSION IN BREAST CARCINOMA
We found a positive correlation between ER and PR protein expression (r ¼ 0.394, P , 0.001) ( Table 4) . Positive correlations between CSN6 and HER2/neu were found (r ¼ 0.206, P ¼ 0.048), whereas there was negative correlations between CSN6 and mutant-type P53 (r ¼ 20.417, P , 0.001); (Table 4) . However, no correlation was found among CSN6, ER, PR and Ki-67 expression (r ¼ 20.035, P ¼ 0.740; r ¼ 0.001, P ¼ 0.992; r ¼ 0.047, P ¼ 0.653, respectively) ( Table 4) .
PROGNOSTIC ANALYSIS
Overall, 18 (19.57%) patients received no further treatment after surgery, 31 (33.70%) received chemotherapy and Fig. 2A ). Subgroup analysis demonstrated that CSN6-positive expression was not associated with breast cancer-specific survival in 44 lymph node-negative cases (P ¼ 0.232, log-rank test, Fig. 2B ), whereas CSN6 expression was associated with breast cancer-specific survival in 48 lymph node-positive cases (P ¼ 0.024, log-rank test, Fig. 2C ). Furthermore, we observed the relationship between CSN6 status and breast cancer relapse-free survival. It was observed that CSN6 was associated with breast cancer relapse-free survival (P ¼ 0.030, log-rank test). Subgroup analysis demonstrated that CSN6 expression was associated with breast cancer relapse-free survival in the lymph node-positive group (P ¼ 0.038, log-rank test), but not in the lymph node-negative group (P ¼ 0.695, log-rank test). After performing a Cox regression, CSN6 was not shown to be an independent prognostic factor of breast cancer.
DISCUSSION
Breast cancer is a clinically heterogeneous disease. A significant number of new anticancer agents involving hormone treatment for hormone-receptor-positive patients, bisphosphonates and trastuzumab for HER2/neu-overexpressing tumors, have been developed and shown to be effective in the treatment of breast cancer (15, 16) . However, the strategies of these treatments are limited to a subset of patients whose tumors express ER, PR, HER2/neu, P53, Ki-67 and so on. Therefore, the status of these proteins has prognostic ramifications for breast cancer. Therefore, much investigation is focused on understanding the clinical significance of known markers, finding relationships between them and discovering new ones-for finding the optimal utilization of the available therapies and development of novel therapies based on the improved cancer models (17) . CSN6 holds an MPN (Mpr1p and Pad1pN-terminal) domain, which of its deneddylation activity toward cullin-RING ubiquitin ligases (CRLs) may coordinate CRL-mediated ubiquitination activity. Some evidence shows that CSN6 is involved in ubiquitin-mediated proteolysis of important mediators in carcinogenesis and cancer progression (18) . Levels of the wild-type p53 protein are predominantly regulated by its proteolytic turnover. MDM2 has one of the most important RING domain-containing ubiquitin ligase activity for controlling the half-life of the tumor suppressor wild-type p53 protein (19) . Recent studies indicate that CSN6 is an oncogene with positive activity toward MDM2, and that the effect of CSN6 on the MDM2 -p53 axis is important for DNA damage response and tumorigenesis (13) . CSN6 is utilized as a marker of initiation and progression in tumors; however, very little is known about its functions or prognosis and correlation with mutant-type P53.
A study based on Western patients suggested that amplification of CSN6 was detected in 77.6% of 58 breast cancer samples collection using a quantitative PCR. Univariate analysis showed that there was a significant positive correlation between CSN6 gene copy number and tumor size at the time of surgical resection. In univariate and multivariate analyses, no significant associations were found between the CSN6 gene copy number and ER expression, PR expression, HER2/neu overexpression or lymph node metastasis (13) .
To this day, the studies addressing the correlation between CSN6 expression and CSN6 gene copy number in Asian breast cancer patients have never been reported. In our study, positive expression of CSN6 protein was highly expressed in breast cancer by immunochemistry and related to tumor size, corroborating the previous findings. Interestingly, we observed that CSN6-positive expression was associated with poor prognosis in all the cases and the lymph node-positive group-supporting the concept that CSN6-positive cancer cells may have higher capability of tumor initiation and progression through prognostic analysis. There are some differences between our results and previously reported results. Zhao et al. reported that CSN6 was not found to be associated with lymph node metastasis in their study (13) . There may be some reasons causing these differences, such as different sub-groups and ethnic differences. Another reason is that CSN6 may have function as an oncogene to provide growth advantage, as reflected not only by increase in tumor size, but also in metastasis and progression. After univariate and multivariate analyses, CSN6 expression was significantly negatively related to the expression of mutant-type P53 in our study. Our findings indicate that CSN6 may differentially control cancer invasion and metastasis between wild-type and mutanttype P53 tumors. In a subset of these tumors, overexpression of CSN6 is mutually exclusive to p53 mutation, which suggests that overexpression of CSN6 may substitute for the inactivation of p53 by mutants. However, the specific role of CSN6 in breast cancer needed further investigation. 
CONCLUSION
The present study found that CSN6 was highly expressed in breast cancers and correlates with clinicopathological and immunohistochemical characteristics. It demonstrated that CSN6 might be a new potential biomarker for breast cancer. However, the underlying mechanisms of CSN6's involvement are still unclear. Hence, the prognostic impact of CSN6 expression in breast carcinomas needs further investigation.
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